Haisco Pharmaceutical Group (SHE:002653) has received approval from China's National Medical Products Administration to proceed with clinical trials for a new indication of its novel drug, HSK39297 tablets.

The approval is for the use of HSK39297 tablets to treat Generalized Severe Myasthenia Gravis (GMG), a rare autoimmune disease that causes systemic muscle weakness. GMG was recognized as a rare disease in China in 2018.

Haisco said current targeted treatments for GMG in China are primarily inconvenient injected biologics, which can affect patient compliance.